ContraFect(OTC) CFRXQ

Market Cap$1.10K

Since IPO (2014)-100%

5 Year-100%

1 Year-80%

1 Month+9,900%

$0.00

+0.00%

+0.00Today

ContraFect last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-14

ContraFect stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9,900%	USD 0.00	2026-07-07
1 month	+9,900%	USD 0.00	2026-07-07
3 month	+9,900%	USD 0.00	2026-05-11
Year to date	+900%	USD 0.00	2025-12-30
1 year	-80%	USD 0.00	2025-08-06
3 year	-99.99%	USD 0.97	2023-08-15
5 year	-100%	USD 299.20	2021-08-13
Since inception	-100%	USD 3,480.00	2014-09-15

ContraFect Financials at a Glance

Market Cap

$1.10K

Revenue (TTM)

$0.00

Net Income (TTM)

-$24.14M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-79.22 (Low)

Dividend

$0.00

Beta (Volatility)

-79.22 (Low)

Price

$0.00

Volume

125

Open

$0.00

Price

$0.00

Volume

125

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 17, 2026

Dividend

$0.00

Beta (Volatility)

-79.22 (Low)

Price

$0.00

Volume

125

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 17, 2026

CFRXQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ContraFect

ContraFect Corporation is a biotechnology firm focused on developing innovative therapeutic proteins and antibodies to combat life-threatening infectious diseases. The company is currently advancing its lead candidate, Exebacase, through Phase III clinical trials, targeting drug-resistant infections.

Products and Services

Exebacase: A lysin enzyme for treating Staphylococcus aureus bacteremia
CF-296: An engineered lysin for invasive Staphylococcus aureus infections
CF-370: An investigational therapy for Pseudomonas aeruginosa infections

Growth Outlook

Exebacase is in Phase III trials, indicating significant progress towards market entry
CF-370 has entered Phase 1 trials, expanding the product pipeline
Partnership with The Rockefeller University enhances research capabilities

Financial Highlights

Q3 2023 net income of -$5.36 million, showing a decrease from Q2
Cash and cash equivalents at $5.41 million as of September 30, 2023
Operating expenses totaled $6.68 million in Q3 2023, reflecting ongoing R&D investments

ContraFect Corporation is positioned in the biotechnology sector, focusing on addressing critical healthcare challenges. The company's innovative approach to treating drug-resistant infections could potentially lead to significant advancements in patient care. With ongoing clinical trials and strategic partnerships, ContraFect aims to enhance its product offerings and market presence. The financial data indicates a commitment to research and development, although the company continues to operate at a loss as it advances its clinical programs.

AI Generated • Aug 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Roger J. Pomerantz, MD

Website

www.contrafect.com

Headquarters

Yonkers, NY 10701, US

CFRXQ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-347.26%

Return on Capital

N/A

Return on Assets

-315.07%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.10K

Shares Outstanding

10.70M

Volume

125

Avg. Volume

17.587

Financials (TTM)

Gross Profit

-$159.00K

Operating Income

-$30.21M

EBITDA

-$30.06M

Operating Cash Flow

-$35.59M

Capital Expenditure

-$63.00K

Free Cash Flow

-$35.65M

Cash & ST Invst.

$5.41M

Total Debt

$2.55M

ContraFect Performance Analysis

ContraFect annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 0	N/A
2022	2022-12-31	USD 0	N/A

ContraFect sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	N/A
Q1	2023-03-31	N/A
Q2	2023-06-30	N/A
Q3	2023-09-30	N/A

ContraFect annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -44.12	N/A
2022	2022-12-31	USD -124.97	183.2%

ContraFect sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	53.5%
Q1	2023-03-31	95.7%
Q2	2023-06-30	-181.2%
Q3	2023-09-30	74.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$39.00K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

$1.10K

N/A

Market Cap/Employee

$47.83

N/A

Employees

N/A

Net Income

-$5.36M

+68.6%

EBITDA

-$6.64M

+53.1%

Quarterly Fundamentals

Name

Q3 2023YOY CHG

Total Cash

$5.41M

-69.3%

Total Debt

$2.55M

-14.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.87M

-19.0%

Short Term Debt

$680.00K

+1.9%

Return on Assets

-3.15%

N/A

Return on Invested Capital

353.35%

N/A

Free Cash Flow

-$8.67M

+10.4%

Operating Cash Flow

-$8.67M

+10.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RASPActavia Life Sciences, Inc.

RASPActavia Life Sciences, Inc.$0.00+0.00%

PAIOFPaion AG

PAIOFPaion AG$0.07+0.00%

CELUCelularity Inc.

CELUCelularity Inc.$0.70+0.03%

DWTXDogwood Therapeutics, Inc.

DWTXDogwood Therapeutics, Inc.$2.06-4.19%

INOInovio Pharmaceuticals, Inc.

INOInovio Pharmaceuticals, Inc.$1.15+5.50%

CDXSCodexis, Inc.

CDXSCodexis, Inc.$1.59+1.92%

MESOMesoblast Limited

MESOMesoblast Limited$17.02+9.14%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.61-0.02%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$146.23+0.04%

IPSTIp Strategy

IPSTIp Strategy$7.39+2.36%

NVDANvidia

NVDANvidia$225.01-0.00%

NOKNokia

NOKNokia$10.78+0.00%

INTCIntel

INTCIntel$103.49+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$8.69+0.02%

Questions About CFRXQ

What is the current price of ContraFect?

ContraFect is trading at $0.00 per share.

What is the 52-week range for ContraFect?

Over the past 52 weeks, ContraFect has traded between $0.00 and $0.00.

How much debt does ContraFect have?

As of the most recent reporting period, ContraFect reported total debt of $2.88M.

How much cash does ContraFect have on hand?

ContraFect reported $8.91M in cash and cash equivalents in its most recent financial results.

What is ContraFect’s dividend yield?

ContraFect does not currently have a dividend yield.

ContraFect(OTC) CFRXQ

ContraFect Financials at a Glance

CFRXQ News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ContraFect

CFRXQ Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ContraFect Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CFRXQ

What is the current price of ContraFect?

What is the 52-week range for ContraFect?

How much debt does ContraFect have?

How much cash does ContraFect have on hand?

What is ContraFect’s dividend yield?

Premium Investing Services